Arcellx Q2 net loss $27.2M; earns $68M milestone from Kite; IND cleared for myasthenia gravis

Arcellx, Inc.

2024-Q2 EPS reported -$0.65 revenue$66,640,000

Earned $68M milestone from Kite for iMMagine-1 enrollment in multiple myeloma.
Cash, equivalents, and marketable securities $646.8M as of June 30, 2024; funds operations into 2027.
Collaboration revenue $27.4M (up from $14.3M YoY); net loss $27.2M vs $23.9M YoY.
FDA cleared anito-cel IND for myasthenia gravis, a chronic autoimmune disease; wholly owned by Arcellx.
Kite initiated global Phase 3 iMMagine-3; abstract submitted for ASH Annual Meeting by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.